Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116861 | 0.86 | RORC (0.47) | ABL1KDM4EGAAMEN1KMT2A | |
| SCHEMBL3921833 | 0.84 | TGFBR1 (0.48) | TGFBR1MAPK14ABL1KDM4EGAA | |
| SCHEMBL4107545 | 0.82 | ADORA3 (0.52) | KDM4EGUSBMEN1KMT2ATSHR | |
| SCHEMBL4108669 | 0.82 | TYMS (0.44) | TGFBR1MAPK14GUSBMEN1KMT2A | |
| SCHEMBL4114211 | 0.80 | ADORA3 (0.45) | TGFBR1MAPK14KDM4EGAAPOLB | |
| SCHEMBL4107454 | 0.80 | KMO (0.47) | TGFBR1MAPK14ABL1KDM4EGAA | |
| SCHEMBL4113880 | 0.77 | ABL1 (0.48) | TGFBR1MAPK14ABL1KDM4EGAA | |
| SCHEMBL4525328 | 0.76 | FGFR1 (0.54) | ABL1KDM4EGAAMEN1KMT2A | |
| SCHEMBL3933091 | 0.74 | ADORA3 (0.56) | TGFBR1KDM4EGAAMEN1KMT2A | |
| SCHEMBL4102669 | 0.69 | PIK3CG (0.36) | TGFBR1MAPK14POLBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | TGFBR1 4683/4885MAPK14 3835/4885ABL1 1437/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | TGFBR1 954/4885MAPK14 2770/4885ABL1 2954/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | TGFBR1 954/4885MAPK14 2770/4885ABL1 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.